Sjögren’s Syndrome-Like Ocular Surface Disease in Thrombospondin-1 Deficient Mice
AUTOR(ES)
Turpie, Bruce
FONTE
American Society for Investigative Pathology
RESUMO
Thrombospondin-1 (TSP-1) is a major activator of latent transforming growth factor-β in vitro as well as in vivo. Mice deficient in TSP-1, despite appearing normal at birth, develop a chronic form of ocular surface disease that is marked by increased apoptosis and deterioration in the lacrimal gland, associated dysfunction, and development of inflammatory infiltrates that result in abnormal tears. The increase in CD4+ T cells in the inflammatory infiltrates of the lacrimal gland, and the presence of anti-Sjögren’s syndrome antigen A and anti-Sjögren’s syndrome antigen B antibodies in the serum resemble autoimmune Sjögren’s syndrome. These mice develop an ocular surface disorder dry eye that includes disruption of the corneal epithelial layer, corneal edema, and a significant decline in conjuctival goblet cells. Externally, several mice develop dry crusty eyes that eventually close. The inflammatory CD4+ T cells detected in the lacrimal gland, as well as those in the periphery of older TSP-1 null mice, secrete interleukin-17A, a cytokine associated with chronic inflammatory diseases. Antigen-presenting cells, derived from TSP-1 null, but not from wild-type mice, activate T cells to promote the Th17 response. Together, these results indicate that TSP-1 deficiency results in a spontaneous form of chronic dry eye and aberrant histopathology associated with Sjögren’s syndrome.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2731132Documentos Relacionados
- Sweet syndrome-like cutaneous drug reaction
- Germline PTEN mutations in Cowden syndrome-like families.
- Aromatase-deficient mice spontaneously develop a lymphoproliferative autoimmune disease resembling Sjögren's syndrome
- Type 2 leprosy reaction with Sweet's syndrome-like presentation
- Kabuki syndrome-like features in monozygotic twin boys with a pseudodicentric chromosome 13.